BioAge Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . BioAge Labs
BIOA Stock   20.10  1.11  5.85%   
BioAge Labs' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing BioAge Labs' valuation are provided below:
Gross Profit
-3.7 M
Market Capitalization
839.2 M
Enterprise Value Revenue
87.1197
Revenue
5.9 M
Earnings Share
13.61
We have found one hundred twenty available fundamental signals for BioAge Labs, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of BioAge Labs prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.

BioAge Labs Total Revenue

0.0

Check BioAge Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAge Labs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 142.8 K, Interest Expense of 3.6 M or Selling General Administrative of 23.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.18. BioAge financial statements analysis is a perfect complement when working with BioAge Labs Valuation or Volatility modules.
  
Build AI portfolio with BioAge Stock
Check out the analysis of BioAge Labs Correlation against competitors.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.

BioAge Labs Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets432.6 M412 M138.4 M
Slightly volatile
Short and Long Term Debt Total7.4 M7.8 M22.1 M
Slightly volatile
Total Current Liabilities30.1 M31.9 M21 M
Pretty Stable
Property Plant And Equipment Net676.3 K711.9 K25.9 M
Slightly volatile
Current Deferred Revenue9.4 M9 M3.5 M
Slightly volatile
Accounts Payable3.5 M1.8 M2.9 M
Very volatile
Cash427.9 M407.5 M103.7 M
Slightly volatile
Non Current Assets Total967 K1 M29.1 M
Slightly volatile
Non Currrent Assets Other205.2 K216 K624.2 K
Slightly volatile
Cash And Short Term Investments427.9 M407.5 M103.7 M
Slightly volatile
Net Receivables5.9 M5.6 M3.3 M
Slightly volatile
Good Will513.8 K562.8 K631 K
Slightly volatile
Common Stock Shares Outstanding18.6 M9.7 M19.4 M
Slightly volatile
Liabilities And Stockholders Equity432.6 M412 M138.4 M
Slightly volatile
Non Current Liabilities Total8 M8.4 M62.4 M
Slightly volatile
Inventory3.4 M5.5 M3.8 M
Slightly volatile
Other Current Assets3 M2.5 M3.6 M
Slightly volatile
Other Stockholder Equity695.1 M662 M223.8 M
Slightly volatile
Total Liabilities38.4 M40.4 M92.1 M
Pretty Stable
Total Current Assets431.2 M410.7 M109.3 M
Slightly volatile
Short Term Debt13.7 M7.1 M8.3 M
Pretty Stable
Intangible Assets5.5 M4.6 M4.5 M
Very volatile
Common Stock328.5 K599.3 K389.7 K
Slightly volatile
Long Term Debt4.8 M2.9 M2.8 M
Slightly volatile
Capital Lease Obligations163.2 K232.3 K84 K
Slightly volatile
Property Plant And Equipment Gross999.5 K1.3 M857.5 K
Slightly volatile
Short and Long Term Debt6.6 M6.9 M3.9 M
Slightly volatile

BioAge Labs Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization142.8 K150.3 K1.9 M
Slightly volatile
Interest Expense3.6 M2.1 M2.8 M
Slightly volatile
Selling General Administrative23.1 M22 M10.3 M
Slightly volatile
Selling And Marketing Expenses2.9 M1.7 M3 M
Slightly volatile
Other Operating Expenses62 M89.9 M52.6 M
Slightly volatile
Research Development71.3 M67.9 M29.4 M
Slightly volatile
Cost Of Revenue27 M25.7 M15.5 M
Slightly volatile
Total Operating Expenses55.5 M89.9 M48.9 M
Slightly volatile
Interest Income11.6 M11.1 M2.4 M
Slightly volatile
Reconciled Depreciation167.9 K192.1 K139.2 K
Slightly volatile

BioAge Labs Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4 M6.3 M4.7 M
Slightly volatile
Begin Period Cash Flow29.7 M22.5 M39.3 M
Very volatile
Depreciation142.8 K150.3 K1.9 M
Slightly volatile
Total Cash From Financing Activities460.3 M438.4 M113.3 M
Slightly volatile
End Period Cash Flow427.9 M407.5 M103.9 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation1.071.970.9786
Slightly volatile
Cash Per Share31.2229.738.5326
Slightly volatile
Income Quality0.810.830.87
Slightly volatile
Current Ratio12.1511.575.8344
Slightly volatile
Capex Per Share0.01870.03070.0168
Slightly volatile
Interest Debt Per Share0.880.930.9259
Slightly volatile
Debt To Assets0.02650.02790.1918
Pretty Stable
Ebt Per Ebit1.181.051.0223
Slightly volatile
Quick Ratio12.1511.575.8344
Slightly volatile
Cash Ratio12.0611.485.7639
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.910.9858
Slightly volatile
Debt Ratio0.02650.02790.1918
Pretty Stable

BioAge Labs Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap109.3 M123 M134.2 M
Slightly volatile
Enterprise Value111.9 M151.5 M120.5 M
Slightly volatile

BioAge Fundamental Market Drivers

About BioAge Labs Financial Statements

BioAge Labs stakeholders use historical fundamental indicators, such as BioAge Labs' revenue or net income, to determine how well the company is positioned to perform in the future. Although BioAge Labs investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioAge Labs' assets and liabilities are reflected in the revenues and expenses on BioAge Labs' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioAge Labs. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue9 M9.4 M
Cost Of Revenue25.7 M27 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
When determining whether BioAge Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioAge Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioage Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioage Labs Stock:
How To Invest In BioAge
Details
Is BioAge Stock a good investment?
Details
What is BioAge Labs' Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of BioAge Labs Correlation against competitors.
For information on how to trade BioAge Stock refer to our How to Trade BioAge Stock guide.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAge Labs. Projected growth potential of BioAge fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive BioAge Labs assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
13.61
Revenue Per Share
0.165
Return On Assets
(0.17)
Return On Equity
(0.26)
Investors evaluate BioAge Labs using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating BioAge Labs' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause BioAge Labs' market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
It's important to distinguish between BioAge Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding BioAge Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, BioAge Labs' market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY